{"name":"Regulus Therapeutics Inc.","slug":"regulus-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":72000,"revenueGrowth":300,"grossMargin":0,"rdSpend":35367000,"netIncome":-46358000,"cash":84181000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"RGLS4326","genericName":"RGLS4326","slug":"rgls4326","indication":"Other","status":"phase_1"},{"name":"RGLS8429","genericName":"RGLS8429","slug":"rgls8429","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"RGLS4326","genericName":"RGLS4326","slug":"rgls4326","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RGLS8429","genericName":"RGLS8429","slug":"rgls8429","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNM1pOa3IwTUxodktJck4xQTBSY0JWMGx1cmdQTldsSnV5LXROQ1R0MzZ4b2xVUGdXTzQ5YWVvSFdYSmlXOHhacVdfTHlTZGc4My1HYlBLSXZRWW9TdHBuWjgzTm9DU2gyQW5lWUpnN1dfc2RYUEViVWJSUzFPUGx2TGZHbzltZVlHblVMVUhPQWRwSktLSVhJVlBUdTJFTGFJd1pn?oc=5","date":"2025-07-31","type":"deal","source":"DCAT Value Chain Insights","summary":"Bio/Pharma Industry Radar: Top Mergers & Acquisitions Thus Far in 2025 - DCAT Value Chain Insights","headline":"Bio/Pharma Industry Radar: Top Mergers & Acquisitions Thus Far in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPaDRPaDNNVWc1T25GWlNuTXRmeFJxWU5oZkVNNlZERF9HQlFfRVpCQV8zYkxVT3VCZFRSdWZwcFNyWnhMZ0xPWk9YVER2U2U2S21hWFNlY0RVMlRvdzBBQXViUlZOVjBSNm5BOXBpRGdydzl3TmFsZ3Jfckk2WmJyaUpMVkNYVzJiY2pBaVAweThYZUU?oc=5","date":"2025-06-26","type":"pipeline","source":"Pharmaceutical Technology","summary":"Novartis concludes Regulus Therapeutics acquisition - Pharmaceutical Technology","headline":"Novartis concludes Regulus Therapeutics acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPVzc1RzVxVFJiWGFkbWNiZVhMT3NSTk11SVo4WlBKblByZXE5MVN5SHAyQllnVzU1WEtCVi1UMDhXMFZwaW1wTTBudHNyeFhSc0FkNlNLcTR2Z2RmOFFxZUhReno4YkR1SnNQZC15VXAxNkZRY3pWNW9xdTA5TDAtUERjVHJFMU1ManQ2cGlkVjZMZXdOVm9KbHNZa3o?oc=5","date":"2025-06-25","type":"pipeline","source":"Novartis","summary":"Novartis completes acquisition of Regulus Therapeutics - Novartis","headline":"Novartis completes acquisition of Regulus Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPVkFkdEl4YW5PU0czeDM0VEE5ZTZueWwzUGZsQUtfdUhtOV9uTWFEOTBZdnR0V01sVE5VV1ZhYXNfM0hCRVlyVXhxU2o5QkNaTDdiOGNxRWI2ZGZsTlEwbUJIVExDUmtVM1YwTno4Zld4LU9YaV9IbGVPV1M5NlBucDlKWWVnVmVKZFdtVnl3UWJHcHg5TW8zam1id0dOVEsyZnc0ZjBlbTVQR1RtUTdhVGIxNzhuUEotSVF6aU5B?oc=5","date":"2025-05-28","type":"pipeline","source":"Fierce Pharma","summary":"Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows - Fierce Pharma","headline":"Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNNE9WT2d5akphdTBybWFwSjVTVVZneGp6YUR5Q3VfWEkxRzE2RklRb3dJMWcyOTVFeW1TR0dTNTkxT2VZV29mYXZEUXlCdjREc0J3aXB4dTczbGEyVkhxWWpSRThweUNlMF92R2QydGd1aEk1Ulc4XzR4WTdWdEZoLUFibEI4MG5NT1BTWEZYTWRsd2ozYU1UMXBjazVBeUk?oc=5","date":"2025-05-12","type":"deal","source":"San Diego Business Journal","summary":"Novartis to Acquire Regulus Therapeutics - San Diego Business Journal","headline":"Novartis to Acquire Regulus Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOekdDLWRCM2VtZi1KSnFOaXhlazJFU1FiTjBQNWl5MnplVmc4Y25CUlNzcHdtNXdxYnFZZEFjVXpLa3hkdHp1WGZKWTVOMmJhdm1Mb2lqS1A1YlhQRTQxWmFtVFpnZWFRa0VrNl9yR2x2UjRGbTR4ejNDSzUtZ3ZOci1YbmtISXF5Q3pKazBpZC1QUEVxUjZSNGFOSkhEN196Uno5UjhHd3RyVTMya2ppZ1N1cw?oc=5","date":"2025-05-02","type":"deal","source":"Los Angeles Times","summary":"Novartis to buy Regulus Therapeutics for as much as $1.7 billion - Los Angeles Times","headline":"Novartis to buy Regulus Therapeutics for as much as $1.7 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOOGpEU2Z3TVhzcEQ1aGRDNVlvVjg3VUxxeERPYVdVYzBqRkx1QTdFZWlXM1R5Yl8yX0FVZmplQUJqbGNXTUk4bGdSNWdIZTliN2NWS0dFSGZtcVMzaHhvaGtfZlRRYWk4bWFJdGJCMUF5ZjV3aUptZklVbjI4VGF6NklVRFpyY0YxcTZvTHRHOVlZOU1tMW12dVZtak9URTJVWVBXc3pSeWpuQU9VS3BrVHpJR2ZrbkF4a3hOTmF6TF94QQ?oc=5","date":"2025-05-01","type":"pipeline","source":"European Pharmaceutical Review","summary":"New $1.7b Novartis acquisition to advance novel microRNA inhibitor | News - European Pharmaceutical Review","headline":"New $1.7b Novartis acquisition to advance novel microRNA inhibitor | News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQTEw1emYtTS1rb18wRGpyeHpsTDcwNnY0ZFE2dzRCcTdxYVN0NTl0VjRldlpMU1hCOVdZZ0MzcFAyRzlFanRNaDNHUEFHTnlkUG4zWnNObFRkQVd4TkZFaVpLZGJDMmJOTVFpWllfZUJMYTN1SXN0N09IcWZRM2RGRHc5WmE0c2NKcUVWNkUyQVJaeWxfSUNsWHQtRkJLMjFIMXdYbEtFQVBKTU9rZWs3NktlVHpHRmRyQ2ZCYW5tSHZoUmNYS3Fj?oc=5","date":"2025-04-30","type":"deal","source":"PR Newswire","summary":"Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG - PR Newswire","headline":"Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPUHg2TTUyM1gyZHYwc2RHcndGb1ZYdkVKWm1GWkZIWWxjc1VNc0NUNGRTNkJWR0htbUhwSmtnd0Y3WU1PbzYzLVQ5aDR5X1VPWllqS0wxMThDSmI5d0lndmRnOXZlY25QWVlISW02R2M5dkdYSnljTXFtb2xxaDl0XzhrRjdwUHBYTGJ0aC1HRlY3VFlH?oc=5","date":"2025-04-30","type":"deal","source":"BioPharma Dive","summary":"Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive","headline":"Novartis to acquire Regulus in deal for kidney disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVkFQbXFMM0hKdkVwcTItS2dsY3dZeWt0N1hyZ05PZHRmalZoVEo5TXh2THV0QWZoU3FUOWY3UmZWZWVRMlo2bW5iVjA2Z1FXZWNySzdjNXo5OWpOOG95VnhNOG9QaWNDWUY3dTBNWEdZNGEydmNQaVlYMFU0SHE4YUNKaUNZMm9Kb0V2VzBkRU5yWmxBNk4yeWZhMXF0bmxETkpjdzI1dUg2WERmQkFVMlNnTkFta0puaHk0?oc=5","date":"2025-04-30","type":"deal","source":"Reuters","summary":"Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal - Reuters","headline":"Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNdXowRi1CZncwcnVpQkFub1BSQmZPbVFzUjR0N3hVNE1FU1JNMzRLMmVEd011V1d6Z3lQemtELW9UVVNndlVYY1JhR3BzZEtldjZpckFyNnZTNFBPbUNveXRFU3ZNTUxuVHBhdXFrV1g4dDdzNGpBaHFmcTJvUjlFRE85MXpTdXlQZll3d18ySjVJNE9BYnRYNmtEdENLbkZoWmZKektWaDVCekRsbWtLM1FlMzh6RXkzOW1tSVJXaTFjT2lnV3FQbGJ0WHNOTS1jbHF0dGRubVZSWjZpYkl5VTlOVklOVmYwTWpNTDU4REloVTduTVZmdC1uYUVES0d1bjhCUUtxOG1zSklBSVg5Zm5n?oc=5","date":"2025-04-30","type":"deal","source":"Novartis","summary":"Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure - Novartis","headline":"Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOSXJiSTBaOWxPNDdRMlowMVFhU3hqMElSbEN0UDRQd2ZOQTVjN3ppenBrTE50S1FaYXdXa3ppMkNoNGMyTXdfR2NPenVKWm1EUHV1MkxfRHR6YXB1TzlXMW5nTE84Ym51OEpOOURSLTlMdGJRVDlId0hYbXpveHZiSEJjU1c0T25nejRBQVppTXVNWDkwRnc?oc=5","date":"2025-04-30","type":"deal","source":"WSJ","summary":"Novartis to Acquire Regulus in $1.7 Billion Deal - WSJ","headline":"Novartis to Acquire Regulus in $1.7 Billion Deal","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":72000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":72000,"period":"2017-12-31"},{"value":18000,"period":"2017-12-31"},{"value":18000,"period":"2017-09-30"},{"value":18000,"period":"2017-06-30"},{"value":18000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":35367000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-46358000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":84181000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}